Table 1.
Summary of KDIGO and American Diabetes Association (ADA) recommendations regarding surveillance among acute kidney injury, chronic kidney disease, and diabetic patient cohorts.
Figure 1.
In each exclusion block, patients can appear in more than one exclusion criteria.
Table 2.
Demographics and Baseline Characteristics.
Figure 2.
Cumulative Incidences of (A) Any Proteinuria Measurement, (B) Quantitative Proteinuria Measurement, and (C) PTH or Phosphorus Measurement Each Analyzed with Improvement in Kidney Function, and Death or Hospice as Competing Risks for one year following hospital discharge among Patients with Baseline eGFR<60 mL/min/1.73 m2.
Figure 3.
Cumulative Incidences of (A) Any Proteinuria Measurement, (B) Quantitative Proteinuria Measurement, and (C) PTH or Phosphorus Measurement Each Analyzed with Improvement in Kidney Function, and Death or Hospice as Competing Risks for one year following hospital discharge among Patients with Baseline eGFR≥60 mL/min/1.73 m2.
Table 3.
(A) Urinary Proteinuria and (B) Quantitative Proteinuria each in Competing Incidence Functions with Improvement in Kidney Function (eGFR≥60 mL/min/1.73 m2) and Death or Hospice Care.
Table 4.
Cumulative Incidences for Receipt of PTH or Phosphorus, Improvement in Kidney Function (eGFR≥60 mL/min/1.73 m2), and Death or Hospice Care in the entire cohort, among those with baseline eGFR≥60 mL/min/1.73 m2, and among those with baseline eGFR<60 mL/min/1.73 m2.
Figure 4.
Proportion of patients Remaining at Risk (Still Eligible without Receipt) for Measurement of Any Proteinuria, Quantitative Proteinuria, or PTH or Phosphorus at one year post-discharge in the entire cohort, among those with baseline eGFR≥60 mL/min/1.73 m2, and among those with baseline eGFR<60 mL/min/1.73 m2.
Indicates the cumulative incidence probabilities with competing risks from Improvement in Kidney Function (eGFR≥60 mL/min/1.73 m2) and Death or Hospice Care, and 95% confidence limits included.